Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases in the United States. The company offers Nyloxin/Nyloxin Extra Strength, an over-the-counter (OTC) pain reliever; Pet Pain-Away, a homeopathic, nonnarcotic, non...
Nutra Pharma reported revenue of $385,307 for fiscal year 2025, down 1.7% from fiscal year 2024, and net income of -$2.05 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $57,922, down 52.6% from a year before. Its market capitalization was $715,972 as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
No profile data available.